159 research outputs found
Synthesis of 2-Methyl-3-indolylacetic Derivatives as Anti-Inflammatory Agents That Inhibit Preferentially Cyclooxygenase 1 without Gastric Damage
Novel substituted 2-methyl-3-indolylacetic derivatives were synthesized and evaluated for their activity in vitro and in vivo on COX-1 and COX-2. Active compounds were screened to determine their gastrointestinal tolerability in vivo in the rat. Results showed that 3 and 4 preferentially inhibited COX-1 in vitro and in vivo. MD simulations indicated an induced fit for COX-1 but not for COX-2, probably because of a lower plasticity of the latter
Non-Natural Linker Configuration in 2,6-Dipeptidyl-Anthraquinones Enhances the Inhibition of TAR RNA Binding/Annealing Activities by HIV-1 NC and Tat Proteins
The HIV-1 nucleocapsid (NC) protein represents an excellent molecular target for the development of antiretrovirals
by virtue of its well-characterized chaperone activities, which play pivotal roles in essential steps of the viral life cycle.
Our ongoing search for candidates able to impair NC binding/annealing activities led to the identification of peptidylanthraquinones
as a promising class of nucleic acid ligands. Seeking to elucidate the inhibition determinants and increase the
potency of this class of compounds, we have now explored the effects of chirality in the linker connecting the planar nucleus to
the basic side chains. We show here that the non-natural linker configuration imparted unexpected TAR RNA targeting
properties to the 2,6-peptidyl-anthraquinones and significantly enhanced their potency. Even if the new compounds were able to
interact directly with the NC protein, they manifested a consistently higher affinity for the TAR RNA substrate and their TARbinding
properties mirrored their ability to interfere with NC-TAR interactions. Based on these findings, we propose that the
viral Tat protein, sharing the same RNA substrate but acting in distinct phases of the viral life cycle, constitutes an additional
druggable target for this class of peptidyl-anthraquinones. The inhibition of Tat-TAR interaction for the test compounds
correlated again with their TAR-binding properties, while simultaneously failing to demonstrate any direct Tat-binding
capabilities. These considerations highlighted the importance of TAR RNA in the elucidation of their inhibition mechanism,
rather than direct protein inhibition. We have therefore identified anti-TAR compounds with dual in vitro inhibitory activity on
different viral proteins, demonstrating that it is possible to develop multitarget compounds capable of interfering with processes
mediated by the interactions of this essential RNA domain of HIV-1 genome with NC and Tat proteins
Design, Synthesis and Evaluation of Novel Molecular Hybrids between Antiglaucoma Drugs and H2S Donors
Glaucoma is a group of eye diseases consisting of optic nerve damage with corresponding loss of field vision and blindness. Hydrogen sulfide (H2S) is a gaseous neurotransmitter implicated in various pathophysiological processes. It is involved in the pathological mechanism of glaucomatous neuropathy and exerts promising effects in the treatment of this disease. In this work, we designed and synthetized new molecular hybrids between antiglaucoma drugs and H2S donors to combine the pharmacological effect of both moieties, providing a heightened therapy. Brinzolamide, betaxolol and brimonidine were linked to different H2S donors. The H2S-releasing properties of the new compounds were evaluated in a phosphate buffer solution by the amperometric approach, and evaluated in human primary corneal epithelial cells (HCEs) by spectrofluorometric measurements. Experimental data showed that compounds 1c, 1d and 3d were the hybrids with the best properties, characterized by a significant and long-lasting production of the gasotransmitter both in the aqueous solution (in the presence of L-cysteine) and in the intracellular environment. Because, to date, the donation of H2S by antiglaucoma H2S donor hybrids using non-immortalized corneal cells has never been reported, these results pave the way to further investigation of the potential efficacy of the newly synthesized compounds
Antagonizing S1P3 receptor with Cell-Penetrating Pepducins in Skeletal Muscle Fibrosis
Bioactive lipids, derived from the metabolism of plasma membrane, are important mediators of cellular signaling in vertebrates. In recent years there has been a growing interest on sphingosine-1-phosphate (S1P) which is the final metabolite produced during the sequential degradation of plasma membrane glycosphingolipids and sphingomyelin. The S1P acts through five known subtypes of heptameric G-protein coupled receptors (GPCR), namely S1P1-S1P5 (S1PR). Recent evidence indicates that S1P signaling axis contributes to the development and maintenance of the fibrotic process [1]. Fibrosis is a pathological condition that can affect every organ, consequence of a persisting inflammatory and tissue remodeling condition. In different fibrotic models an extensive crosstalk between TGFβ and S1P signaling axis has been demonstrated. S1P3 plays a pivotal role in fibrosis development in different tissues such as skeletal muscle, liver, and kidney [2]. Thus, selective antagonists of the S1P3 receptor could be useful to deeply study its role in fibrosis as well as to develop new therapeutic entities to treat fibrotic diseases.
Pepducins specifically target the intracellular loops, acting as allosteric modulators of GPCR activity. Using this approach, we have synthesized a pepducin based S1P3 antagonist namely KRX-725-II (Myristoyl-GRPYDAN-NH2) [3]. Here to improve the S1P1 vs S1P3 selectivity, we have synthesized several derivatives of KRX-725-II pointing our attention on the aromatic residue of the sequence, Tyr4, and with the aim to introduce molecular constraints. The new molecular entities have been evaluated for their selectivity profile by using mouse aortas. This screening allowed us to identify compounds V and VII (embodying respectively L- and D-Tic) as the most selective S1P3 antagonists. The selected compounds also displayed the ability to significantly reduce the profibrotic action of TGFβ1 in C2C12 myoblasts. To explain the higher selectivity observed for compounds V and VII, they were analyzed by Molecular Dynamics (MD) Simulations. The middle conformations of V and VII were compared by superimposing their GRP residues, which adopt a similar backbone orientation (see Figure). This revealed that the DAN residues with β-turn-like motif are located on opposite sides of the plane defined by the L- or D-Tic residue. This difference may explain, in structural terms, the selective S1P3 antagonism of V and VII in comparison to the unselective antagonist KRX-725-II, whose flexibility seems to be high enough for the adaptation to the binding regions of the individual receptor subtypes S1P1 and S1P3. Peptides V and VII possess, indeed, a highly constrained D- or L-Tic residue that hinder the pharmacophore from interacting properly with the binding pocket of the S1P1 receptor, therefore leading to S1P3 selectivity
Structure-activity Relationships Study of Isothiocyanates for H2S Releasing Properties: 3-Pyridyl-Isothiocyanate as a New Promising Cardioprotective Agent
Abstract A library of forty-five isothiocyanates, selected for their different chemical properties, has been evaluated for its hydrogen sulfide (H2S) releasing capacity. The obtained results allowed to correlate several factors such as steric hindrance, electronic effects and position of the substituents to the observed H2S production. Moreover, the chemical-physical profiles of the selected compounds have been studied by an in silico approach and from a combination of the obtained results, 3-pyridyl-isothiocyanate (25) has been selected as the most promising one. A detailed pharmacological characterization of its cardioprotective action has been performed. The results herein obtained strongly indicate 3-pyridyl-isothiocyanate (25) as a suitable pharmacological option in anti-ischemic therapy
Heavy Metals Size Distribution in PM10 and Environmental-Sanitary Risk Analysis in Acerra (Italy)
The present research has been focused on the evaluation of seasonal changes in mass concentrations and compositions of heavy metals in Particular Matters (PM)10 collected from a typical urban-industrial site in Acerra, a city located in an area called "triangle of death". No significant (p < 0.05) seasonal variation was evidenced for the PM10 concentration, but in all the seasons (except for autumn) exceedances of daily concentrations (50 μg m−3) were observed. Airborne PM was analyzed for these heavy metals: Al, As, Cd, Co, Cr, Cu, Fe, Mn, Ni, Pb, Sb, V and Zn, which represented about 8% of the PM10 concentrations. None of the metals classified by IARC as carcinogenic in humans (group 1) exceeded on average the annual EU's and Italy's limit. For the mentioned heavy metals the enrichment factors (EnFs) were analyzed and highlighted high enrichment for Cd, Sb, Pb, As, Cu and Zn. Principal component analysis (PCA) for the heavy metals in PM10 identified oil combustion, vehicle and industrial emissions as major sources. To assess the health risk related to the inhalation to airborne PM10 metals, we applied the Cancer Risk (CR) and Target Hazard Quotient (THQ). The results showed that the CR was similar for a child and an adult, while the THQ proved to be higher for a child than for an adult. The low PM metals risk in the urban industrial site was in agreement with the ongoing lowering trend of metals in Italy and Europe
Development of 1,2,3-Triazole-Based Sphingosine Kinase Inhibitors and Their Evaluation as Antiproliferative Agents
Two series of N-(aryl)-1-(hydroxyalkyl)pyrrolidine-2-carboxamides (2a-2g and 3a-3g) and 1,4-disubstituted 1,2,3-triazoles (5a-5h and 8a-8h) were synthesized. All the compounds, containing a lipophilic tail and a polar headgroup, were evaluated as sphingosine kinase (SphK) inhibitors by assessing their ability to interfere with the acetylcholine (Ach) induced relaxation of aortic rings pre-contracted with phenylephrine. Moreover, their antiproliferative activity was tested on several cell lines expressing both SphK1 and SphK2. Compounds 5h and 8f, identified as the most efficient antiproliferative agents, showed a different selectivity profile, with 8f being selective for SphK1
Antagonizing S1P3 Receptor with Cell-Penetrating Pepducins in Skeletal Muscle Fibrosis
S1P is the final product of sphingolipid metabolism, which interacts with five widely expressed GPCRs (S1P1-5). Increasing numbers of studies have indicated the importance of S1P3 in various pathophysiological processes. Recently, we have identified a pepducin (compound KRX-725-II) acting as an S1P3 receptor antagonist. Here, aiming to optimize the activity and selectivity profile of the described compound, we have synthesized a series of derivatives in which Tyr, in position 4, has been substituted with several natural aromatic and unnatural aromatic and non-aromatic amino acids. All the compounds were evaluated for their ability to inhibit vascular relaxation induced by KRX-725 (as S1P3 selective pepducin agonist) and KRX-722 (an S1P1-selective pepducin agonist). Those selective towards S1P3 (compounds V and VII) were also evaluated for their ability to inhibit skeletal muscle fibrosis. Finally, molecular dynamics simulations were performed to derive information on the preferred conformations of selective and unselective antagonists
Development, validation of LC-MS/MS method and determination of pharmacokinetic parameters of the stroke neuroprotectant Neurounina-1 in Beagle dog plasma after intravenous administration
Neurounina-1 [chemical name: 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one] is a new compound provided with relevant neuroprotective effect during stroke and in neonatal hypoxia by increasing the Na+/Ca2+ exchanger (NCX) isoforms NCX1 and NCX2 activity. This study shows for the first time, the development and validation of a sensitive and selective method for analysis of neurounina-1 in beagle dog plasma by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The sample preparation consisted of extraction of the analyte and the internal standard (IS) (ropivacaine) from plasma (50 mu L) by liquid-liquid extraction using acetonitrile (100 mu L). The selected reaction monitoring mode of the positive ion was performed and the precursor to the product ion transitions of m/z 365 > 83 and m/z 275 > 126 were used to measure the derivative of neurounina-1 and ropivacaine. The chromatographic separation was achieved using a Phenomenex C18 Luna (150 mm x 4.6 mm x 5 mu m) analytical column with an isocratic mobile phase composed of methanol/acetonitrile/water (50/40/10, v/v/v) + 0.1% formic acid + 1 M ammonium formate. The method was linear over a concentration range of 1-500 ng/mL. The method was applied to evaluate the pharmacokinetics of neurounina-1 after a single intravenous administration of three different doses (0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) to beagle dogs (n = 5). The mean AUC(0-tlast) values were 26.10, 115.81, and 257.28 ng*h/mL following intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. Linear pharmacokinetics was observed up to 1.0 mg/kg. The neurounina-1 was rapidly eliminated, with mean CL values of 46.24, 47.57, and 69.15 L/h, Vd of 130.31, 154.15, and 210.79 L and t(1/2) of 2.14, 2.54, and 2.04 h after intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. This new analytical method allows the rapid determination of the neurounina-1, a new developed compound, able to exert a remarkable neuroprotective effect in the low nanomolar range10CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPsem informação2016/22506-1This pharmacokinetic trial was supported by Programma Operativo Nazionale (PON_01602 and PON03PE_00146_1) from MIUR, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP – Grant n° 2016/22506-1
Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration
Neurounina-1 [chemical name: 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one] is a new compound provided with relevant neuroprotective effect during stroke and in neonatal hypoxia by increasing the Na+/Ca2+ exchanger (NCX) isoforms NCX1 and NCX2 activity. This study shows for the first time, the development and validation of a sensitive and selective method for analysis of neurounina-1 in beagle dog plasma by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The sample preparation consisted of extraction of the analyte and the internal standard (IS) (ropivacaine) from plasma (50 μL) by liquid-liquid extraction using acetonitrile (100 μL). The selected reaction monitoring mode of the positive ion was performed and the precursor to the product ion transitions of m/z 365 > 83 and m/z 275 > 126 were used to measure the derivative of neurounina-1 and ropivacaine. The chromatographic separation was achieved using a Phenomenex C18 Luna (150 mm × 4.6 mm × 5 μm) analytical column with an isocratic mobile phase composed of methanol/acetonitrile/water (50/40/10, v/v/v) + 0.1% formic acid + 1 M ammonium formate. The method was linear over a concentration range of 1–500 ng/mL. The method was applied to evaluate the pharmacokinetics of neurounina-1 after a single intravenous administration of three different doses (0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) to beagle dogs (n = 5). The mean AUC0-tlast values were 26.10, 115.81, and 257.28 ng∗h/mL following intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. Linear pharmacokinetics was observed up to 1.0 mg/kg. The neurounina-1 was rapidly eliminated, with mean CL values of 46.24, 47.57, and 69.15 L/h, Vd of 130.31, 154.15, and 210.79 L and t1/2 of 2.14, 2.54, and 2.04 h after intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. This new analytical method allows the rapid determination of the neurounina-1, a new developed compound, able to exert a remarkable neuroprotective effect in the low nanomolar range
- …